cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.10048013
title: snapp_responses.csv

description: Data on each of 117897 unique responses to tasks (i.e. participant-image combinations)
DOI: 10.6084/m9.figshare.10048025
title: users.csv

description: User regions (personal details such as email addresses have been removed)
DOI: 10.6084/m9.figshare.10048196.v3
title: Supplementary Material for: Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial

description: <b><i>Background:</i></b> Among diabetics, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality, and progression of their underlying disease. Finerenone is a novel, non-steroidal, selective mineralocorticoid-receptor antagonist which has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD), while revealing only a low risk of hyperkalemia. However, the effect of finerenone on renal and CV outcomes has not been investigated in long-term trials yet. <b><i>Methods:</i></b> The Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease ­(FIDELIO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important renal and CV outcomes in T2D patients with CKD. FIDELIO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 5.5 years. FIDELIO-DKD randomized 5,734 patients with an estimated glomerular filtration rate (eGFR) ≥25–&lt;75 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30–≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of kidney failure, a sustained decrease of eGFR ≥40% from baseline over at least 4 weeks, or renal death. <b><i>Conclusion:</i></b> FIDELIO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of renal and CV events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen.
DOI: 10.6084/m9.figshare.10048022
title: snapp_tasks.csv

description: Task list for the challenge
DOI: 10.6084/m9.figshare.10048028.v1
title: snapp-image-metadata-mistakes.csv

description: Image metadata with mistakes fixed and documented
DOI: 10.6084/m9.figshare.10048013.v1
title: snapp_responses.csv

description: Data on each of 117897 unique responses to tasks (i.e. participant-image combinations)
DOI: 10.6084/m9.figshare.10048022.v1
title: snapp_tasks.csv

description: Task list for the challenge
DOI: 10.6084/m9.figshare.10048025.v1
title: users.csv

description: User regions (personal details such as email addresses have been removed)
DOI: 10.5281/zenodo.3541572
title: Data for the publication "Singular charge fluctuations at a magnetic quantum critical point"

description: Data sets of the figures in the publication "Singular charge fluctuations at a magnetic quantum critical point" Preprint: arXiv:1808.02296
DOI: 10.6084/m9.figshare.10048196.v4
title: Supplementary Material for: Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial

description: <b><i>Background:</i></b> Among diabetics, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality, and progression of their underlying disease. Finerenone is a novel, non-steroidal, selective mineralocorticoid-receptor antagonist which has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD), while revealing only a low risk of hyperkalemia. However, the effect of finerenone on renal and CV outcomes has not been investigated in long-term trials yet. <b><i>Methods:</i></b> The Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease ­(FIDELIO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important renal and CV outcomes in T2D patients with CKD. FIDELIO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 5.5 years. FIDELIO-DKD randomized 5,734 patients with an estimated glomerular filtration rate (eGFR) ≥25–&lt;75 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30–≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of kidney failure, a sustained decrease of eGFR ≥40% from baseline over at least 4 weeks, or renal death. <b><i>Conclusion:</i></b> FIDELIO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of renal and CV events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen.
DOI: 10.5281/zenodo.3541571
title: Data for the publication "Singular charge fluctuations at a magnetic quantum critical point"

description: Data sets of the figures in the publication "Singular charge fluctuations at a magnetic quantum critical point" Preprint: arXiv:1808.02296
DOI: 10.6084/m9.figshare.10048196.v6
title: Supplementary Material for: Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial

description: <b><i>Background:</i></b> Among diabetics, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality, and progression of their underlying disease. Finerenone is a novel, non-steroidal, selective mineralocorticoid-receptor antagonist which has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD), while revealing only a low risk of hyperkalemia. However, the effect of finerenone on renal and CV outcomes has not been investigated in long-term trials yet. <b><i>Methods:</i></b> The Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease ­(FIDELIO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important renal and CV outcomes in T2D patients with CKD. FIDELIO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 5.5 years. FIDELIO-DKD randomized 5,734 patients with an estimated glomerular filtration rate (eGFR) ≥25–&lt;75 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30–≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of kidney failure, a sustained decrease of eGFR ≥40% from baseline over at least 4 weeks, or renal death. <b><i>Conclusion:</i></b> FIDELIO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of renal and CV events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen.
DOI: 10.6084/m9.figshare.10048196.v5
title: Supplementary Material for: Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial

description: <b><i>Background:</i></b> Among diabetics, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality, and progression of their underlying disease. Finerenone is a novel, non-steroidal, selective mineralocorticoid-receptor antagonist which has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD), while revealing only a low risk of hyperkalemia. However, the effect of finerenone on renal and CV outcomes has not been investigated in long-term trials yet. <b><i>Methods:</i></b> The Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease ­(FIDELIO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important renal and CV outcomes in T2D patients with CKD. FIDELIO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 5.5 years. FIDELIO-DKD randomized 5,734 patients with an estimated glomerular filtration rate (eGFR) ≥25–&lt;75 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30–≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of kidney failure, a sustained decrease of eGFR ≥40% from baseline over at least 4 weeks, or renal death. <b><i>Conclusion:</i></b> FIDELIO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of renal and CV events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen.
DOI: 10.6084/m9.figshare.10047962
title: snapp_media.csv

description: Metadata for each of 1068 unique images used in the challenge
DOI: 10.6084/m9.figshare.10047962.v1
title: snapp_media.csv

description: Metadata for each of 1068 unique images used in the challenge
DOI: 10.6084/m9.figshare.10047947
title: Additional file 2: of Neuropathology and cognitive performance in self-reported cognitively healthy centenarians

description: Table S2. Subject demographics and overview of neuropathological hallmarks of centenarians. (XLSX 34 kb)
DOI: 10.6084/m9.figshare.10047950
title: Additional file 3: of Neuropathology and cognitive performance in self-reported cognitively healthy centenarians

description: Table S3. a, b and c: Pearson correlation coefficient (a), p-values (b) and false discovery rates (c) for the correlation plot in Fig. 3. (XLSX 29 kb)
DOI: 10.6084/m9.figshare.10047947.v1
title: Additional file 2: of Neuropathology and cognitive performance in self-reported cognitively healthy centenarians

description: Table S2. Subject demographics and overview of neuropathological hallmarks of centenarians. (XLSX 34 kb)
DOI: 10.6084/m9.figshare.10047950.v1
title: Additional file 3: of Neuropathology and cognitive performance in self-reported cognitively healthy centenarians

description: Table S3. a, b and c: Pearson correlation coefficient (a), p-values (b) and false discovery rates (c) for the correlation plot in Fig. 3. (XLSX 29 kb)
DOI: 10.6084/m9.figshare.10047944
title: Additional file 1: of Neuropathology and cognitive performance in self-reported cognitively healthy centenarians

description: Table S1. Overview of all variables used in correlation plot in Fig. 3. (XLSX 10 kb)
DOI: 10.6084/m9.figshare.10047944.v1
title: Additional file 1: of Neuropathology and cognitive performance in self-reported cognitively healthy centenarians

description: Table S1. Overview of all variables used in correlation plot in Fig. 3. (XLSX 10 kb)
DOI: 10.6084/m9.figshare.10047839
title: Additional file 1: of A meta-analysis of hypoxia inducible factor 1-alpha (HIF1A) gene polymorphisms: association with cancers

description: Heterogeneity analysis of HIF1A 1772 C/T. (XLSX 14Â kb)
DOI: 10.6084/m9.figshare.10047842
title: Additional file 2: of A meta-analysis of hypoxia inducible factor 1-alpha (HIF1A) gene polymorphisms: association with cancers

description: Heterogeneity analysis of A polymorphism/A. (XLSX 12Â kb)
DOI: 10.6084/m9.figshare.10047842.v1
title: Additional file 2: of A meta-analysis of hypoxia inducible factor 1-alpha (HIF1A) gene polymorphisms: association with cancers

description: Heterogeneity analysis of A polymorphism/A. (XLSX 12Â kb)
DOI: 10.6084/m9.figshare.10047839.v1
title: Additional file 1: of A meta-analysis of hypoxia inducible factor 1-alpha (HIF1A) gene polymorphisms: association with cancers

description: Heterogeneity analysis of HIF1A 1772 C/T. (XLSX 14Â kb)
DOI: 10.6084/m9.figshare.10047824
title: Additional file 1: of Novel digenic inheritance of PCDH15 and USH1G underlies profound non-syndromic hearing impairment

description: Supplementary data associated with this manuscript consists of Table S1. Variants of interest identified by exome sequencing. This list includes variants in this study that were tested for segregation. Annotations and population frequencies are listed. (XLSX 12 kb).
DOI: 10.6084/m9.figshare.10047824.v1
title: Additional file 1: of Novel digenic inheritance of PCDH15 and USH1G underlies profound non-syndromic hearing impairment

description: Supplementary data associated with this manuscript consists of Table S1. Variants of interest identified by exome sequencing. This list includes variants in this study that were tested for segregation. Annotations and population frequencies are listed. (XLSX 12 kb).
DOI: 10.6084/m9.figshare.10047686
title: Additional file 6: of Unique microglia recovery population revealed by single-cell RNAseq following neurodegeneration

description: Table S2. Overlap of the 72 common differentially regulated genes (Fig. 2 and Table 2) with the consensus microglia gene expression signature induced by aging, primed and neurodegenerative conditions reported in Table S5 [19]. (XLSX 13 kb)
DOI: 10.6084/m9.figshare.10047683
title: Additional file 5: of Unique microglia recovery population revealed by single-cell RNAseq following neurodegeneration

description: Table S1. Fold changes and adjusted P values of all 5820 genes included in the comparative transcriptomic analysis. (XLSX 479 kb)
DOI: 10.6084/m9.figshare.10047686.v1
title: Additional file 6: of Unique microglia recovery population revealed by single-cell RNAseq following neurodegeneration

description: Table S2. Overlap of the 72 common differentially regulated genes (Fig. 2 and Table 2) with the consensus microglia gene expression signature induced by aging, primed and neurodegenerative conditions reported in Table S5 [19]. (XLSX 13 kb)
DOI: 10.6084/m9.figshare.10047668
title: Additional file 5: of Gene expression profiles at different stages for formation of pearl sac and pearl in the pearl oyster Pinctada fucata

description: Table S7. Details of 192 biomineralization-related genes. (XLSX 26 kb)
DOI: 10.6084/m9.figshare.10047683.v1
title: Additional file 5: of Unique microglia recovery population revealed by single-cell RNAseq following neurodegeneration

description: Table S1. Fold changes and adjusted P values of all 5820 genes included in the comparative transcriptomic analysis. (XLSX 479 kb)
DOI: 10.6084/m9.figshare.10047665
title: Additional file 4: of Gene expression profiles at different stages for formation of pearl sac and pearl in the pearl oyster Pinctada fucata

description: Table S4. Up- and down-regulated DEGs involved in KEGG immune pathways. (XLSX 12 kb)
DOI: 10.6084/m9.figshare.10047668.v1
title: Additional file 5: of Gene expression profiles at different stages for formation of pearl sac and pearl in the pearl oyster Pinctada fucata

description: Table S7. Details of 192 biomineralization-related genes. (XLSX 26 kb)
DOI: 10.6084/m9.figshare.10047659
title: Additional file 2: of Gene expression profiles at different stages for formation of pearl sac and pearl in the pearl oyster Pinctada fucata

description: Table S2. GO analysis. Summary of three functional GO categories for up- and down-regulated DEGs at different time points. (XLSX 257 kb)
DOI: 10.6084/m9.figshare.10047662
title: Additional file 3: of Gene expression profiles at different stages for formation of pearl sac and pearl in the pearl oyster Pinctada fucata

description: Table S3. GO enrichment analysis for immune-related DEGs at 0 h – 24 h and 48 h – 1 w time points. (XLSX 39 kb)
DOI: 10.6084/m9.figshare.10047662.v1
title: Additional file 3: of Gene expression profiles at different stages for formation of pearl sac and pearl in the pearl oyster Pinctada fucata

description: Table S3. GO enrichment analysis for immune-related DEGs at 0 h – 24 h and 48 h – 1 w time points. (XLSX 39 kb)
DOI: 10.6084/m9.figshare.10047665.v1
title: Additional file 4: of Gene expression profiles at different stages for formation of pearl sac and pearl in the pearl oyster Pinctada fucata

description: Table S4. Up- and down-regulated DEGs involved in KEGG immune pathways. (XLSX 12 kb)
DOI: 10.6084/m9.figshare.10047659.v1
title: Additional file 2: of Gene expression profiles at different stages for formation of pearl sac and pearl in the pearl oyster Pinctada fucata

description: Table S2. GO analysis. Summary of three functional GO categories for up- and down-regulated DEGs at different time points. (XLSX 257 kb)
DOI: 10.6084/m9.figshare.10047620
title: MOESM1 of Rice of Northeast India harbor rich genetic diversity as measured by SSR markers and Zn/Fe content

description: Additional file 1. The genotype data of indigenous rice cultivars of NE India and improved varieties.
DOI: 10.6084/m9.figshare.10047626
title: MOESM3 of Rice of Northeast India harbor rich genetic diversity as measured by SSR markers and Zn/Fe content

description: Additional file 3. Pairwise Population Fst Values.
DOI: 10.6084/m9.figshare.10047629
title: MOESM4 of Rice of Northeast India harbor rich genetic diversity as measured by SSR markers and Zn/Fe content

description: Additional file 4. Summary of analysis of molecular variance.
DOI: 10.6084/m9.figshare.10047620.v1
title: MOESM1 of Rice of Northeast India harbor rich genetic diversity as measured by SSR markers and Zn/Fe content

description: Additional file 1. The genotype data of indigenous rice cultivars of NE India and improved varieties.
DOI: 10.6084/m9.figshare.10047623
title: MOESM2 of Rice of Northeast India harbor rich genetic diversity as measured by SSR markers and Zn/Fe content

description: Additional file 2. Pairwise Population Matrix of Nei Genetic Identity.
DOI: 10.6084/m9.figshare.10047626.v1
title: MOESM3 of Rice of Northeast India harbor rich genetic diversity as measured by SSR markers and Zn/Fe content

description: Additional file 3. Pairwise Population Fst Values.
DOI: 10.6084/m9.figshare.10047629.v1
title: MOESM4 of Rice of Northeast India harbor rich genetic diversity as measured by SSR markers and Zn/Fe content

description: Additional file 4. Summary of analysis of molecular variance.
DOI: 10.6084/m9.figshare.10047623.v1
title: MOESM2 of Rice of Northeast India harbor rich genetic diversity as measured by SSR markers and Zn/Fe content

description: Additional file 2. Pairwise Population Matrix of Nei Genetic Identity.
DOI: 10.6084/m9.figshare.10047608
title: Additional file 1: of Factors associated with regular counselling attendance of HIV outpatients of a national referral hospital in Jakarta, Indonesia: a cross sectional study

description: RSPI-SS HIV Counseling Study. (XLSX 281 kb)
DOI: 10.6084/m9.figshare.10047608.v1
title: Additional file 1: of Factors associated with regular counselling attendance of HIV outpatients of a national referral hospital in Jakarta, Indonesia: a cross sectional study

description: RSPI-SS HIV Counseling Study. (XLSX 281 kb)
DOI: 10.6084/m9.figshare.10047569
title: Additional file 9: of Optical and physical mapping with local finishing enables megabase-scale resolution of agronomically important regions in the wheat genome

description: 7A QTL analysis and coordinates in RAC875 × Kukri cross. (XLSX 24 kb)
DOI: 10.6084/m9.figshare.10047563
title: Additional file 7: of Optical and physical mapping with local finishing enables megabase-scale resolution of agronomically important regions in the wheat genome

description: IWGSC RefSeq v1.0 7A gene IDs corrected by manual curation. (XLSX 21 kb)
DOI: 10.6084/m9.figshare.10047563.v1
title: Additional file 7: of Optical and physical mapping with local finishing enables megabase-scale resolution of agronomically important regions in the wheat genome

description: IWGSC RefSeq v1.0 7A gene IDs corrected by manual curation. (XLSX 21 kb)
DOI: 10.6084/m9.figshare.10047569.v1
title: Additional file 9: of Optical and physical mapping with local finishing enables megabase-scale resolution of agronomically important regions in the wheat genome

description: 7A QTL analysis and coordinates in RAC875 × Kukri cross. (XLSX 24 kb)
DOI: 10.6084/m9.figshare.10047560
title: Additional file 6: of Optical and physical mapping with local finishing enables megabase-scale resolution of agronomically important regions in the wheat genome

description: IWGSC RefSeq v1.0 7A intra-scaffold gaps related to Gydle scaffolds and contigs plus bridging sequences. (XLSX 398 kb)
DOI: 10.6084/m9.figshare.10047548
title: Additional file 3: of Optical and physical mapping with local finishing enables megabase-scale resolution of agronomically important regions in the wheat genome

description: a Combining the MAGIC 8-way cross 7A and Chinese Spring x Renan 7A maps [42, 43]. b Curated genetic map of 7A for anchoring the genome sequence. (ZIP 112 kb)
DOI: 10.6084/m9.figshare.10047554
title: Additional file 5: of Optical and physical mapping with local finishing enables megabase-scale resolution of agronomically important regions in the wheat genome

description: a IWGSC RefSeq 7A inter-scaffold gaps related to PacBio and Gydle scaffolds. b Gydle island IDs related to Bionano maps and BAC sets. (ZIP 51 kb)
DOI: 10.6084/m9.figshare.10047560.v1
title: Additional file 6: of Optical and physical mapping with local finishing enables megabase-scale resolution of agronomically important regions in the wheat genome

description: IWGSC RefSeq v1.0 7A intra-scaffold gaps related to Gydle scaffolds and contigs plus bridging sequences. (XLSX 398 kb)
DOI: 10.6084/m9.figshare.10047548.v1
title: Additional file 3: of Optical and physical mapping with local finishing enables megabase-scale resolution of agronomically important regions in the wheat genome

description: a Combining the MAGIC 8-way cross 7A and Chinese Spring x Renan 7A maps [42, 43]. b Curated genetic map of 7A for anchoring the genome sequence. (ZIP 112 kb)
DOI: 10.6084/m9.figshare.10047554.v1
title: Additional file 5: of Optical and physical mapping with local finishing enables megabase-scale resolution of agronomically important regions in the wheat genome

description: a IWGSC RefSeq 7A inter-scaffold gaps related to PacBio and Gydle scaffolds. b Gydle island IDs related to Bionano maps and BAC sets. (ZIP 51 kb)
DOI: 10.6084/m9.figshare.10047530
title: Additional file 10: of Optical and physical mapping with local finishing enables megabase-scale resolution of agronomically important regions in the wheat genome

description: Finished 7A yield region assembly BAC sets. (XLSX 10 kb)
DOI: 10.6084/m9.figshare.10047533
title: Additional file 11: of Optical and physical mapping with local finishing enables megabase-scale resolution of agronomically important regions in the wheat genome

description: 7A yield region annotation. (XLSX 20 kb)
DOI: 10.6084/m9.figshare.10047530.v1
title: Additional file 10: of Optical and physical mapping with local finishing enables megabase-scale resolution of agronomically important regions in the wheat genome

description: Finished 7A yield region assembly BAC sets. (XLSX 10 kb)
DOI: 10.6084/m9.figshare.10047533.v1
title: Additional file 11: of Optical and physical mapping with local finishing enables megabase-scale resolution of agronomically important regions in the wheat genome

description: 7A yield region annotation. (XLSX 20 kb)
DOI: 10.6084/m9.figshare.10047470
title: MOESM1 of Ecological status of high altitude medicinal plants and their sustainability: Lingshi, Bhutan

description: Additional file 1. Geo-location, vegetation cover and habitat description for priority species at different survey points.
DOI: 10.6084/m9.figshare.10047473
title: MOESM2 of Ecological status of high altitude medicinal plants and their sustainability: Lingshi, Bhutan

description: Additional file 2. Priority species plant density at different survey points.